Abstract: The invention relates to the field of binding molecules comprising at least one single variable antibody domain, targeted at receptors present on myofibroblasts and/or hepatic stellate cells (HSCs). The invention also relates to a binding molecule comprising at least two single variable antibody domains, each targeting a receptor on HSCs and/or on myofibroblasts. The invention further relates to nucleic acids encoding such binding molecules, a host cell for expression of such binding molecules and to methods for preparing such binding molecules. The invention further relates to pharmaceutical compositions that comprise such binding molecule and to uses of such binding molecules and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.

Abstract: Methods for preparing a cell targeting conjugate, which conjugate comprises a cell binding moiety conjugated to a secondary functional moiety. The disclosure further relates to the cell targeting conjugates obtainable by the method, to a pharmaceutical composition comprising the conjugates and to the secondary functional moieties as such. The disclosure also relates to the use of the cell targeting conjugates in the treatment of cancer.

Abstract: The disclosure relates to secondary functional moieties comprising a transition metal-based linker and a primary functional moiety bound thereto. The disclosure also relates to cell targeting conjugates comprising a linker of the invention. The disclosure further relates to a medicament comprising the cell targeting conjugate and to the use of the cell targeting conjugates in the diagnosis and treatment of cancer.

Abstract: A first aspect of the disclosure relates to a method for preparing cell-targeting conjugates by coupling at least one functional moiety, such as a therapeutic compound, diagnostic compound or chelating agent to a targeting moiety. A second aspect of this disclosure relates to the cell-targeting conjugates obtainable with this method. A third aspect of the disclosure described herein relates to pharmaceutical compositions comprising the cell-targeting conjugates.

Abstract: This disclosure describes a method for preparing stable cell targeting conjugates. A further aspect of this disclosure relates to the stable cell targeting conjugates obtainable by the method and to pharmaceutical compositions comprising these stable cell targeting conjugates. A last aspect of this disclosure relates to the use of these conjugates and pharmaceutical compositions as a medicament.

Abstract: Cell targeting conjugates that comprise a targeting moiety and one or more functional moieties bound thereto via a linker, wherein the linker comprises a transition metal complex and wherein at least 90% of the conjugates have a ratio of functional moieties to targeting moieties (DAR) of or less. A pharmaceutical composition comprising the cell targeting conjugates and the use of the conjugates and composition as a medicament, in particular, in the treatment of cancer.

Abstract: This disclosure describes a method for preparing stable cell targeting conjugates. A further aspect of this disclosure relates to the stable cell targeting conjugates obtainable by the method and to pharmaceutical compositions comprising these stable cell targeting conjugates. A last aspect of this disclosure relates to the use of these conjugates and pharmaceutical compositions as a medicament.

Abstract: A first aspect of the disclosure relates to a method for preparing cell-targeting conjugates by coupling at least one functional moiety, such as a therapeutic compound, diagnostic compound or chelating agent to a targeting moiety. A second aspect of this disclosure relates to the cell-targeting conjugates obtainable with this method. A third aspect of the disclosure described herein relates to pharmaceutical compositions comprising the cell-targeting conjugates.

Abstract: The invention provides a method for stably cross-linking a first nucleic acid sequence selected for being stably cross-linked in the presence of a second nucleic acid sequence selected for not being stably cross-linked in a nucleic acid molecule. The method comprises providing a nucleic acid sequence that is complementary to the first nucleic acid sequence; hybridizing the first nucleic acid sequence to its complementary sequence; and stably cross-linking the first nucleic acid sequence to the complementary sequence.

Abstract: The invention provides a method for stably cross-linking a first nucleic acid sequence selected for being stably cross-linked in the presence of a second nucleic acid sequence selected for not being stably cross-linked in a nucleic acid molecule. The method comprises providing a nucleic acid sequence that is complementary to the first nucleic acid sequence; hybridizing the first nucleic acid sequence to its complementary sequence; and stably cross-linking the first nucleic acid sequence to the complementary sequence.

Abstract: The invention relates to a method for distinguishing at least two target bio-organic molecules with dyes selected from a pool of at least two dyes, the method comprising: (a) providing a first set of at least two probes, wherein each probe recognizes a target bio-organic molecule in a first set of target bio-organic molecules, and wherein each probe is distinctly-labelled with primary labels that are distinct from one another due to the presence of dyes in distinct ratios; (b) providing a second set of probes distinctly-labelled with said primary labels described in step (a), wherein each probe in said second probe set recognizes a target bio-organic molecule in a second set of target bio-organic molecules; wherein each probe in said first or second probe set is further labelled with the same first binary label, wherein said first binary label is distinct from said primary labels; and (c) contacting said at least two target bio-organic molecules with said probe sets, wherein said target bio-organic molecules

Abstract: The invention relates to a method for identifying a Mycobacterium species comprising the steps of:

Abstract: The invention relates to a method for identifying a Mycobacterium species comprising the steps of: a) contacting at least one immuno-cross reactive antigen component of a mycobacterial species with a sample of a body fluid of a human or animal individual; b) contacting at least one antibody, which is capable of reacting with a mycobacterial antigen, with said body fluid sample; c) detecting the presence of antigen-antibody complexes, and identifying the Mycobacterium species present in said body fluid sample.

Abstract: The invention relates to a method for identifying a Mycobacterium species responsible for a mycobacterial infection in human or animal, comprising selecting a suitable mycobacterial species and strain; preparing at least one mycobacterial antigen, respectively antigen preparation; binding the antigen, respectively the antigen preparation to a suitable carrier; causing the binding antigen to react with antibodies from serum of an individual infected with a Mycobacterium species; making visible antigen-antibody reactions for a suitable antibody (sub-)class; and identifying the responsible Mycobacterium species on the basis of the reactions which are made visible. The invention further provides a diagnostic kit which takes the form of a dip-stick on which is arranged a carrier strip with mycobacterial antigens binding thereto, and means for visualizing antigen-antibody reactions occurring on the carrier after contact with the serum for testing.

Abstract: The invention relates to a method for identifying a Mycobacterium species responsible for a mycobacterial infection in human or animal, comprising selecting a suitable mycobacterial species and strain; preparing at least one mycobacterial antigen, respectively antigen preparation; binding the antigen, respectively the antigen preparation to a suitable carrier; causing the binding antigen to react with antibodies from serum of an individual infected with a Mycobacterium species; making visible antigen-antibody reactions for a suitable antibody (sub-)class; and identifying the responsible Mycobacterium species on the basis of the reactions which are made visible. The invention further provides a diagnostic kit which takes the form of a dip-stick on which is arranged a carrier strip with mycobacterial antigens binding thereto, and means for visualizing antigen-antibody reactions occurring on the carrier after contact with the serum for testing.

Abstract: The Invention relates to a method for providing at least one selected sequence in a nucleic acid with interstrand cross-links. The method comprises hybridizing at least one selected single strand sequence with a complementary single strand nucleic acid or a functional analogue thereof. The selected sequence or complementary nucleic acid or both comprise a cross-linking agent. The invention also relates to a method, referred to as COBRA, for the labeling of a set of at least two bio-organic molecules with a set of at least two colors, comprising generating said set of colors through combining ratio labeling with binary labeling.

Abstract: The Invention relates to a method for providing at least one selected sequence in a nucleic acid with interstrand cross-links. The method comprises hybridizing at least one selected single strand sequence with a complementary single strand nucleic acid or a functional analogue thereof. The selected sequence or complementary nucleic acid or both comprise a cross-linking agent. The invention also relates to a method, referred to as COBRA, for the labeling of a set of at least two bio-organic molecules with a set of at least two colors, comprising generating said set of colors through combining ratio labeling with binary labeling.

Abstract: The present invention is concerned with a trans-platinum based compound for use in a method for labelling a bio-organic molecule, having formula (I), wherein A represents a reactive moiety for attachment to a label, D represents a reactive moiety for attachment to a bio-organic molecule, and X1 and X2 represent the same or different inert moieties.

Abstract: A method for identifying a Mycobacterium species responsible for a mycobacterial infection in human or animal, comprising selecting a suitable mycobacterial species and strain; preparing at least one mycobacterial antigen, respectively antigen preparation; binding the antigen, respectively the antigen preparation to a suitable carrier, causing the binding antigen to react with antibodies from serum of an individual infected with a Mycobacterium species; making visible antigen-antibody reactions for a suitable antibody (sub-)class; and identifying the responsible Mycobacterium on the basis of the reactions which are made visible. The invention further provides a diagnostic kit which takes the form of a dip-stick on which is arranged a carrier strip with mycobacterial antigens binding thereto, and visualizing reagents antigen-antibody reactions occurring on the carrier after contact with the serum for testing.